Literature DB >> 23579549

Mycobacterial ocular inflammation: delay in diagnosis and other factors impacting morbidity.

Sarju S Patel1, Nehali V Saraiya, Howard H Tessler, Debra A Goldstein.   

Abstract

IMPORTANCE: The reported outcomes of ocular mycobacterial infection are commonly unfavorable. This study is among the first to elucidate factors associated with poor outcomes, as well as highlight the continued controversies in therapy, particularly the role of oral corticosteroids.
OBJECTIVE: To describe presentations and outcomes of mycobacterial ocular disease in the Midwestern United States. DESIGN Retrospective case series.
SETTING: A university-based uveitis clinic. PARTICIPANTS: Twenty-six eyes of 17 patients with mycobacterial ocular inflammatory disease seen at University of Illinois at Chicago from 1995 to 2010. MAIN OUTCOME MEASURES: Bivariate and regression analyses were performed to assess factors associated with delay in referral, relapse, and irreversible visual acuity loss (≤ 20/200).
RESULTS: Of 17 patients, 13 had isolated ocular disease, 1 had miliary tuberculosis (TB), 2 had TB lymphadenopathy, and 1 had active pulmonary TB. Fourteen had Mycobacterium tuberculosis and 3 had nontuberculous mycobacterial infection. Chest imaging was consistent with granulomatous disease in 46.7%. Average delay from ocular disease onset to uveitis service referral was 755.3 days. Posterior uveitis and non-Hispanic white race were associated with increased delay. A relapsing course was observed in posterior uveitis (odds ratio [OR], 20.0; 95% CI, 1.39-287; P = .03) and those treated with systemic steroids for eye disease (OR, 10.1; 95% CI,1.60-64.0; P = .01). Disease control was achieved in 81%, although 38.5% had profound visual loss, associated with age older than 50 years and delay in diagnosis. Patients diagnosed after 500 days from initial ocular symptoms were more likely to lose vision (OR, 20.0; 95% CI, 1.41-282; P = .03).
CONCLUSIONS: Ocular mycobacterial infection occurs in nonendemic areas and cannot be ruled out with negative chest imaging. Tuberculosis and atypical mycobacterial infection should be in the differential diagnosis of ocular inflammation, regardless of patient ethnicity. Significant delays exist in instituting antimicrobial treatment, associated with increased morbidity. Early referral is necessary for patients not responding appropriately to anti-inflammatory therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23579549     DOI: 10.1001/jamaophthalmol.2013.71

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  27 in total

1.  Intraocular tuberculosis presenting as a large anterior chamber mass.

Authors:  Trucian A Ostheimer; James P Dunn; Charles G Eberhart; Bryn M Burkholder
Journal:  Ocul Immunol Inflamm       Date:  2014-04-25       Impact factor: 3.070

2.  Treatment outcome in patients with presumed tubercular uveitis at a tertiary referral eye care centre in Singapore.

Authors:  Leslie Ang; Aera Kee; Tun Hang Yeo; V G Dinesh; Su Ling Ho; Stephen C Teoh; Rupesh Agrawal
Journal:  Int Ophthalmol       Date:  2016-12-29       Impact factor: 2.031

3.  Incidence of ocular inflammation among patients with active tuberculosis or nontuberculous mycobacterial infections in a tertiary hospital in Japan.

Authors:  Hiromi Ohara; Yosuke Harada; Tomona Hiyama; Ken Yamane; Maria Higaki; Takayuki Kobayashi; Yasuhiko Ikegami; Yuki Yuasa; Yoshiaki Kiuchi
Journal:  Int Ophthalmol       Date:  2021-01-21       Impact factor: 2.031

Review 4.  Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis.

Authors:  Ae Ra Kee; Julio J Gonzalez-Lopez; Aws Al-Hity; Bhaskar Gupta; Cecilia S Lee; Dinesh Visva Gunasekeran; Nirmal Jayabalan; Robert Grant; Onn Min Kon; Vishali Gupta; Mark Westcott; Carlos Pavesio; Rupesh Agrawal
Journal:  Surv Ophthalmol       Date:  2016-03-10       Impact factor: 6.048

5.  Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1.

Authors:  Rupesh Agrawal; Dinesh Visva Gunasekeran; Robert Grant; Aniruddha Agarwal; Onn Min Kon; Quan Dong Nguyen; Carlos Pavesio; Vishali Gupta
Journal:  JAMA Ophthalmol       Date:  2017-12-01       Impact factor: 7.389

6.  Early treatment of tuberculous uveitis improves visual outcome: a 10-year cohort study.

Authors:  Luis Anibarro; Eliana Cortés; Ana Chouza; Alberto Parafita-Fernández; Juan Carlos García; Alberto Pena; Carlos Fernández-Cid; África González-Fernández
Journal:  Infection       Date:  2018-06-04       Impact factor: 3.553

7.  Tuberculosis of the eye in Italy: a forgotten extrapulmonary localization.

Authors:  M S Tognon; M Fiscon; P Mirabelli; G Graziani; M Peracchi; A Sattin; S Marinello; F Vianello; D Sgarabotto
Journal:  Infection       Date:  2013-11-26       Impact factor: 3.553

8.  Classification Criteria for Tubercular Uveitis.

Authors: 
Journal:  Am J Ophthalmol       Date:  2021-05-11       Impact factor: 5.488

9.  Case report: atypical presentation of Mycobacterium tuberculosis uveitis preceding nodular scleritis.

Authors:  Sunee Chansangpetch; Anita Manassakorn; Prasart Laksanaphuk; Usanee Reinprayoon
Journal:  BMC Infect Dis       Date:  2015-10-28       Impact factor: 3.090

10.  Anti-tubercular therapy alone for treatment of isolated tubercular retinal vasculitis.

Authors:  Anup Kelgaonkar; Vishal Govindhari; Ashish Khalsa; Soumyava Basu
Journal:  Eye (Lond)       Date:  2021-08-09       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.